LNCap clone FGC

LNCap clone FGC/LNCap clone FGC细胞系/LNCap clone FGC细胞株/LNCap clone FGC人前列腺癌细胞

Cell line name LNCaP clone FGC

Synonyms LNCaP-Clone-FGC; LNCaP.FGC; LNCaP-FGC; LNCaP FGC; LNCAPCLONEFGC; LNCaP-ATCC; LNCaP Fast Growing Colony

Accession CVCL_1379

Resource Identification Initiative To cite this cell line use: LNCaP clone FGC (RRID:CVCL_1379)

Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: TCGA-110-CL cell line panel.

Population: Caucasian.

Doubling time: 43 hours (PubMed=15389782); ~34 hours (ATCC=CRL-1740); ~36 hours (PBCF); 38.71 hours (JWGray panel).

Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).

Omics: CRISPR phenotypic screen.

Omics: Deep exome analysis.

Omics: Deep proteome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Omics: Transcriptome analysis by serial analysis of gene expression (SAGE).

Misspelling: LNCaP.FCG; Note=Occasionally.

Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.

PubMed=8104329; DOI=10.1002/pros.2990230206

Carroll A.G., Voeller H.J., Sugars L., Gelmann E.P.

p53 oncogene mutations in three human prostate cancer cell lines.

Prostate 23:123-134(1993)

 

PubMed=10092147; DOI=10.1007/s002400050082

Konig J.J., Teubel W.J., van Steenbrugge G.J., Romijn J.C., Hagemeijer A.

Characterization of chromosome 8 aberrations in the prostate cancer cell line LNCaP-FGC and sublines.

Urol. Res. 27:3-8(1999)

 

PubMed=11172901; DOI=10.1016/S0165-4608(00)00339-3

Strefford J.C., Lillington D.M., Young B.D., Oliver R.T.D.

The use of multicolor fluorescence technologies in the characterization of prostate carcinoma cell lines: a comparison of multiplex fluorescence in situ hybridization and spectral karyotyping data.

Cancer Genet. Cytogenet. 124:112-121(2001)

 

PubMed=12725112; DOI=10.1385/1-59259-372-0:21

Russell P.J., Kingsley E.A.

Human prostate cancer cell lines.

Methods Mol. Med. 81:21-39(2003)

 

PubMed=15389782; DOI=10.1002/pros.20145

Gustavsson H., Welen K., Damber J.-E.

Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis.

Prostate 62:364-373(2005)

 

PubMed=15833837; DOI=10.1158/0008-5472.CAN-04-3218

Lin B.-Y., White J.T., Lu W., Xie T., Utleg A.G., Yan X.-W., Yi E.C., Shannon P., Khrebtukova I., Lange P.H., Goodlett D.R., Zhou D.-X., Vasicek T.J., Hood L.E.

Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease.

Cancer Res. 65:3081-3091(2005)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)